MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC San Diego – April 10, 2013 – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology...
Oxford Immunotec wins 2013 Red Herring Top 100 Award Oxford, UK and Marlborough, MA – 11 April 2013 – Oxford Immunotec is pleased to announce today that it has won a place in Red Herring‘s Top 100 Europe list for 2013. Red Herring’s Top 100 Europe list has...
Chimerix Announces Pricing of Initial Public Offering RESEARCH TRIANGLE PARK, N.C., April 11, 2013 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today...
Durata Therapeutics Closes Public Offering of Common Stock CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) — Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of...
Treato Raises $14.5m from OrbiMed, New Leaf and Reed Elsevier Proceeds to Expedite Commercialization of Treato Pharma Offering and US Expansion, Bringing ‘Voice of the Patient’ to Healthcare Stakeholders Yehud, Israel – April 23, 2013 – Treato, the social...
Spine Wave Announces U.S. FDA’s 510K Clearance of the StaXx® IB System, an Intervertebral Body Fusion Device The StaXx® IB System expands the StaXx® product portfolio and offers the advantage of an Expandable Intervertebral Body Fusion Device with Bone Graft Chambers...
Recent Comments